Dr. Prasad has been a core member of drug discovery teams that discovered multiple drug candidates advanced to various stages of preclinical and clinical development, including Merck’s MK-4965. He was the lead crystallographer and core member of the team that discovered Alogliptin - A Syrrx and Takeda San Diego's DPP4 inhibitor being marketed under the brand name Nesina® to treat type 2 diabetes and the first drug to be discovered using structure-based method at Syrrx. He designed, built and implemented fragment-based crystallography drug discovery technology platforms at Syrrx, Merck and Metabasis. He has co-authored over 40 peer reviewed research articles, holds 6 US and international patents. He serves on the editorial board of Current Protein and Peptide Science, Chemical Sciences Journal and Organic and Medicinal Chemistry International Journal. Dr. Prasad obtained his PhD from the Indian Institute of Science, Bangalore, India and post-doctoral training at the University of Minnesota Medical School and the Scripps Research Institute, La Jolla, California, where he subsequently grew to the ranks of Assistant Professor.
Dr. Williams has over 25 years of small molecule drug discovery and development experience in fields that include oncology and neuroscience. She held positions of increasing responsibility in the Medicinal Chemistry Department at Merck in West Point, PA, including Director of Medicinal Chemistry. She has led multiple small molecule drug discovery programs, highlighted by discovery and development of Telcagepant, the first orally active GPCR receptor antagonist for the treatment of acute migraine that advanced to Phase III clinical trials. Dr. Williams obtained her PhD in Chemistry from Michigan State University and completed post-doctoral studies at Stanford University. She is co-inventor on 46 issued US patents and has co-authored over 45 peer reviewed research publications.
At the Scripps Reference Laboratory Dr. Carney has directed development and validation of esoteric clinical diagnostic assays in the areas of molecular diagnostics, autoimmunity, and specialty coagulation. He then transitioned into drug discovery at Phenomix, where he led development and validation of a panel of five dipeptidyl peptidase (DPP) assays resulting in the discovery DPP4 inhibitor (dutogliptin) for type 2 diabetes that reached Phase 2a clinical trials. As Senior Scientist at CalAsia he has led efforts to develop biochemical and cell-based assays to identify inhibitors/activators for a number of targets. Notably, the Hsp90/TRAP1 inhibitor program resulted in discovery of a potent CNS-permeable dual-acting lead series for treatment of glioblastoma, neurofibromatosis, and other CNS cancers. Dr. Carney obtained his Ph.D. from the University of Maryland where he then attained an Assistant Professorship prior to postdoctoral training at the Scripps Research Institute, La Jolla, CA.